Skip to content
10-Q

Quarterly Report

Protagonist Therapeutics, Inc PTGX

0001558370-25-006530

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 61.98M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $35.11M
Current Liabilities Q1 2025 · Dec 31, 2024 $47.4M
Total Liabilities Q1 2025 · Mar 31, 2025 $53.08M
Total Liabilities Q1 2025 · Dec 31, 2024 $69.43M
Current Assets Q1 2025 · Mar 31, 2025 $605.86M
Current Assets Q1 2025 · Dec 31, 2024 $591.64M
Total Assets Q1 2025 · Mar 31, 2025 $742.13M
Total Assets Q1 2025 · Dec 31, 2024 $744.73M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $97.25M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $172.57M
Shares Diluted Q1 2025 · Mar 31, 2024 63.6M sh
Capex Q1 2025 · Mar 31, 2024 $242K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$27.43M
Stockholders Equity Q1 2025 · Mar 31, 2024 $560.44M
Stockholders Equity Q1 2025 · Dec 31, 2023 $336.68M
Eps Diluted Q1 2025 · Mar 31, 2024 $3.26
Eps Basic Q1 2025 · Mar 31, 2024 $3.41
Sga Expense Q1 2025 · Mar 31, 2024 $14.91M
Rd Expense Q1 2025 · Mar 31, 2024 $33.73M
Net Income Q1 2025 · Mar 31, 2024 $207.34M
Operating Income Q1 2025 · Mar 31, 2024 $206.31M